Comparison of the spinal anti-nociceptive effects of ES-242-1 and MK-801, two different NMDA antagonists, in rats
-
Add time:09/02/2019 Source:sciencedirect.com
The purpose of this study was to determine whether ES-242-1, a novel N-methyl-d-aspartate (NMDA) receptor antagonist of microbial origin, has anti-nociception at the spinal level and to evaluate how its anti-nociceptive effect differs from that of MK-801, a non-competitive NMDA receptor antagonist. Agents were injected intrathecally (0.1, 1.0 and 10 μg) through a previously implanted PE tube in rats. Formalin (2%, 100 μl) was injected subcutaneously into the left hindpaw 15 min after each antagonist administration. Licking time as a nociceptive behavior was measured in three stages after formalin-injection, such as early phase (0–9 min), late first phase (10–29 min) and late second phase (30–60 min). In the early phase, the largest dose of ES-242-1 significantly decreased total licking time, although MK-801 did not show any significant reduction. With the treatment of 1.0 and 10 μg MK-801, total licking time in both late first and second phases was significantly suppressed, although the smallest dose (0.1 μg) of ES-242-1 showed a significant reduction in the late second phase. These results indicate that ES-242-1 is highly effective against tonic pain, such as inflammatory pain.
We also recommend Trading Suppliers and Manufacturers of ES 242-1 (cas 136565-66-7). Pls Click Website Link as below: cas 136565-66-7 suppliers
Prev:Cell culture and biotechnologyProduction of scopadulciol (cas 136565-26-9) by cultured tissues of Scoparia dulcis
Next:High-precision α-particle energies in the decay of Es, Fm, and Md Isotopes) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Studies of electronic configurations in the emission spectra of lanthanides and actinides: application to the interpretation of Es I and Es II, predictions for Fm I09/24/2019
- Artículo originalNuevos biomarcadores en la terapia de resincronización cardiaca. El factor de crecimiento hepatocitario es un predictor de los resultados clínicosNovel Biomarkers in Cardiac Resynchronization Therapy: Hepatocyte Growth Factor Is an Independent Predictor of Clinical Outcome09/10/2019
- OriginalLa simplificación del proceso de diagnóstico de la hepatitis C crónica es una estrategia coste-efectivaThe simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy09/09/2019
- Production and Characterisation of PCL/ES Scaffolds for Bone Tissue Engineering☆09/08/2019
- The neuroprotective properties of ES-242s, novel NMDA receptor antagonists, in neuronal cell culture toxicity studies09/07/2019
- Systematic ReviewEffect of delayed interval delivery of remaining fetus(es) in multiple pregnancies on survival: a systematic review and meta-analysis09/06/2019
- ReviewThe Epigenetic Paradox of Pluripotent ES Cells09/05/2019
- Effects of a novel N-methyl-d-aspartate (NMDA) receptor antagonist, 3,3′-dimethyl-3,4,3′,4′-tetrahydro-6,8,6′8′-tetramethoxy-[10,10′-bi-2-oxanthracene]-4,9,9′(1H,1′H)-triol 4-acetate (ES-242-1), on NMDA-induced increases of intracellular Ca2+ concentration in cultured hippocampal neurons09/04/2019
- High-precision α-particle energies in the decay of Es, Fm, and Md Isotopes09/03/2019


